Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Capital Expenditures (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Capital Expenditures for 4 consecutive years, with $178000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 245.9% to $178000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $229000.0 through Dec 2025, up 2762.5% year-over-year, with the annual reading at $229000.0 for FY2025, 2762.5% up from the prior year.
  • Capital Expenditures for Q4 2025 was $178000.0 at Phathom Pharmaceuticals, up from -$64000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $939000.0 in Q3 2023, with the low at -$1.1 million in Q4 2023.
  • Average Capital Expenditures over 4 years is $24562.5, with a median of $68500.0 recorded in 2024.
  • The sharpest move saw Capital Expenditures soared 600.75% in 2023, then tumbled 600.0% in 2024.
  • Over 4 years, Capital Expenditures stood at -$491000.0 in 2022, then tumbled by 132.38% to -$1.1 million in 2023, then skyrocketed by 89.31% to -$122000.0 in 2024, then surged by 245.9% to $178000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $178000.0, -$64000.0, and $97000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.